Here’s what you should know:
1. Researchers based the compound off Solanum nigrum Linn. In animal models, the compound was 10 times more cytotoxic to HepG2 liver cancer cells than market alternatives.
2. Q BIoMed and The Oklahoma Medical Research Foundation worked to advance the treatment’s development.
3. The compound causes no noticeable side effects in animals models.
4. Q BioMed CEO Denis Corin said in a release, “Our ultimate goal is to use [the compound] as a chemotherapeutic against liver cancer, which has very few therapeutic options.”
More articles on gastroenterology:
GI leader to know: Dr. David Schwartz of Vermont Gastroenterology
Exact Sciences pockets $238M from secondary stock sale — 3 key notes
Clarivate Analytics ranks AGA’s flagship magazine highest of 79 journals
